BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 23276369)

  • 1. Stereotactic body radiotherapy for oligometastases.
    Tree AC; Khoo VS; Eeles RA; Ahmed M; Dearnaley DP; Hawkins MA; Huddart RA; Nutting CM; Ostler PJ; van As NJ
    Lancet Oncol; 2013 Jan; 14(1):e28-37. PubMed ID: 23276369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer.
    Takeda A; Sanuki N; Kunieda E
    World J Gastroenterol; 2014 Apr; 20(15):4220-9. PubMed ID: 24764660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study.
    Mazzola R; Fersino S; Ferrera G; Targher G; Figlia V; Triggiani L; Pasinetti N; Lo Casto A; Ruggieri R; Magrini SM; Alongi F
    Med Oncol; 2018 Aug; 35(9):121. PubMed ID: 30076479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter.
    Thompson R; Cheung P; Chu W; Myrehaug S; Poon I; Sahgal A; Soliman H; Tseng CL; Wong S; Ung Y; Beatriz Kinupe Abrahão A; Erler D; Zhang L; Ko YJ; Chung HT
    Radiother Oncol; 2020 Jan; 142():236-245. PubMed ID: 31543287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
    Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.
    Al-Hallaq HA; Chmura S; Salama JK; Winter KA; Robinson CG; Pisansky TM; Borges V; Lowenstein JR; McNulty S; Galvin JM; Followill DS; Timmerman RD; White JR; Xiao Y; Matuszak MM
    Pract Radiat Oncol; 2016; 6(6):e291-e298. PubMed ID: 27345129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligometastases: history of a hypothesis.
    Milano MT; Biswas T; Simone CB; Lo SS
    Ann Palliat Med; 2021 May; 10(5):5923-5930. PubMed ID: 32279519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
    BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy.
    Sharma A; Duijm M; Oomen-de Hoop E; Aerts JG; Verhoef C; Hoogeman M; Nuyttens JJ
    Acta Oncol; 2018 Aug; 57(8):1031-1037. PubMed ID: 29488414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.
    Fumagalli I; Bibault JE; Dewas S; Kramar A; Mirabel X; Prevost B; Lacornerie T; Jerraya H; Lartigau E
    Radiat Oncol; 2012 Sep; 7():164. PubMed ID: 23014094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
    Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
    BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ablative dose stereotactic body radiation therapy for oligometastatic disease: a prospective single institution study.
    Burkon P; Kazda T; Pospisil P; Slavik M; Kominek L; Selingerova I; Blakaj DM; Prochazka T; Vrzal M; Rehak Z; Slampa P
    Neoplasma; 2019 Mar; 66(2):315-325. PubMed ID: 30509112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease.
    Ahmed KA; Torres-Roca JF
    Cancer Control; 2016 Jan; 23(1):21-9. PubMed ID: 27009453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review.
    Almaghrabi MY; Supiot S; Paris F; Mahé MA; Rio E
    Radiat Oncol; 2012 Aug; 7():126. PubMed ID: 22852764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies.
    Franzese C; Francolini G; Nicosia L; Alongi F; Livi L; Scorsetti M
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):50-56. PubMed ID: 32723486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
    Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
    J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
    Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
    Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Stereotactic Body Radiation Therapy in the Management of Liver Metastases.
    Lee SL; Bassetti MF; Rusthoven CG
    Semin Radiat Oncol; 2023 Apr; 33(2):181-192. PubMed ID: 36990635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.
    Shultz DB; Filippi AR; Thariat J; Mornex F; Loo BW; Ricardi U
    J Thorac Oncol; 2014 Oct; 9(10):1426-33. PubMed ID: 25170641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.